NIH documents show early flaws of $1.6 billion long Covid program

ThestageattheLincolnMemorialinWashingtonforaMarch15rallytoraiseawarenessforlongCovid.RobbHillforTheS 1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha




explore

author:hotspot    Page View:573
Suzanne KreiterGlobe staff

The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

advertisement

Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In